|The myeloperoxidase (MPO)
system is a versatile technology that lends itself to a variety of high
value medical, biodefense, industrial, agricultural, and disinfection applications.
Our primary R&D focus is on the prevention and treatment of serious
and resistant infections.
Prevention of surgical site infection (SSI) is the lead indication for
our proprietary technology. Surgical
site infection is a common nosocomial infection associated with high
morbidity, mortality, and hospital costs.
There is significant opportunity to leverage the unique properties of
the myeloperoxidase (MPO) and eosinophil peroxidase (EPO) technology platform
into multiple indications, including biodefense.